Controversies in Treatment of Small Cell Carcinoma of the Lung

References

• Fox W., Scadding J G. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: Ten-year-follow-up. Lancet 1973; 2: 63–65
   PubMed Web of Science ®Google Scholar
• Salazar O M, Creech R H. “The state of the art” toward defining the role of radiation therapy in the management of small cell bronchogenic carcinoma. Int J Rad Oncol Biol Phys 1980; 6: 1103–1107
   PubMed Web of Science ®Google Scholar
• Matthews M J, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumors in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 1973; 4: 63–67
   Google Scholar
• Greco F A, Richardson R L, Snell J D, et al. Small cell lung cancer: Complete remission and improved survival. Am J Med 1979; 66: 625–630
   PubMed Web of Science ®Google Scholar
• Comis R. Small cell carcinoma of the lung. Cancer Treat Rev 1982; 9: 237–258
   PubMed Web of Science ®Google Scholar
• Morstyn G, Ihde D C, Lichter A S, et al. Small cell lung cancer 1973–1983: Early progress and recent obstacles. Int J Rad Oncol Biol Phys 1984; 10: 515–539
   PubMed Web of Science ®Google Scholar
• Ihde D. Current status of therapy for small cell carcinoma of the lung. Cancer 1984; 54: 2722–2728
   PubMedGoogle Scholar
• Aisner J, Alberto P, Bitran J, et al. Role of chemotherapy in small cell lung cancer: A consensus report of the International Assocation for the Study of Lung Cancer Workshop. Cancer Treat Rep 1983; 67: 37–43
   PubMedGoogle Scholar
• Spremulli E N, Dexter D L. Human tumor cell heterogeneity and metastasis. J Clin Oncol 1983; 8: 496–509
   Google Scholar
• Curt G., Carney D, Cowan R, et al. Unstable methotrexate resistance in human small cell carcinoma associated with double minute chromosomes. N Engl J Med 1983; 308: 199–202
   PubMed Web of Science ®Google Scholar
• Goldie J H, Coldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Goldie J H, Coldman A J, Gudauskas G A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
   PubMedGoogle Scholar
• Alberto P, Berchtold W, Sonntag R, et al. Chemotherapy of small cell carcinoma of the lung: Comparison of cyclic alternative combinations with simultaneous combinations of four and seven agents. Eur J Cancer Clin Oncol 1981; 17: 1027–1033
   PubMedGoogle Scholar
• Osterlind K., Sorenson S, Hansen H, et al. Treatment of advanced small cell carcinoma of the lung: Continuous versus alternating combination chemotherapy. Cancer Res 1983; 43: 6085–6089
   PubMed Web of Science ®Google Scholar
• Havemann K., Harms V., Gropp C, et al. Randomized trial comparing sequential combination chemotherapy (A) with cyclic alternating chemotherapy (B) in small cell lung cancer (SCCL). Proc Am Soc Clin Onc 1984; 3: 232
   Google Scholar
• Ettinger D, Lagakos S. Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine and VP-16 in small-cell carcinoma of the lung. Cancer 1982; 49: 1544–1554
   PubMedGoogle Scholar
• Daniels J R, Chak L Y, Bl Sikic, et al. Chemotherapy of small-cell carcinoma of the lung: A randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984; 2: 1192–1199
   PubMed Web of Science ®Google Scholar
• Krauss S, Lowenbraun S, Bartolucci A, et al. Alternating non-cross resistant drug combinations in the treatment of small-cell carcinoma of the lung. Cancer Clin Trials 1981; 4: 147–153
   PubMedGoogle Scholar
• Aisner J, Whitacre M, Van Echo D A, et al. Combination chemotherapy for small cell carcinoma of the lung: Continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 1982; 66: 221–230
   PubMedGoogle Scholar
• Broder L., Selawry O, Charyulu K, et al. A controlled clinical trial testing two potentially non-cross resistant chemotherapeutic regimens in small-cell carcinoma of the lung. Chest 1981; 79: 327–335
   PubMed Web of Science ®Google Scholar
• Lininger T, Fleming T, Eagen R. Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 1981; 48: 2147–2153
   PubMed Web of Science ®Google Scholar
• Elliot J, Osterlind K, Hansen H. Cyclic alternating “non-cross resistant” chemotherapy in the management of small cell anaplastic carcinoma of the lung. Cancer Treat Rev 1985, in press
   Web of Science ®Google Scholar
• Cohen M H, Broder L E, Fossieck B E, et al. Combination chemotherapy with vincristine, adriamycin and procarbazine in previously treated patients with small cell carcinoma. Cancer Treat Rep 1977; 61: 485–487
   PubMedGoogle Scholar
• Aroney R, Bell D, Chan W, et al. Alternating non-cross-resistant combination of chemotherapy for small cell anaplastic carcinoma of the lung. Cancer 1982; 49: 2449–2454
   PubMed Web of Science ®Google Scholar
• Dillman R, Taetle R, Seagren S, et al. Extensive disease small cell carcinoma of the lung: trial of non-cross-resistant chemotherapy and consolidation radiotherapy. Cancer 1982; 49: 2003–2008
   PubMed Web of Science ®Google Scholar
• Mehta C, Vogl S. Cycling non-cross resistant combination chemotherapy (CT) for small cell lung cancer (SCLC) in remission (R)-50% prolongation of remission duration without prolongation of survival and with enhanced toxicity. Proc Am Soc Clin One 1981; 1: 152
   Google Scholar
• Arnold A M, Williams C J, Mead G M, et al. Combination chemotherapy using high or low dose methotrexate for small cell carcinoma of the lung-a randomized trial. Med Oncol Tumor Pharmacother 1984; 1: 9–14
   PubMedGoogle Scholar
• Sierocki J S, Hilaris B S, Hopfan S, et al. Cis-dichlorodiamineplatinum (II) and VP-16–213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979; 63: 1593–1597
   PubMedGoogle Scholar
• Einhorn L, Williams S, Loehrer P. Platinum (P) + VP-16 chemotherapy for refractory small cell lung cancer (RSCLC). Proc Am Assoc Cancer Res 1984; 25: 174
   Web of Science ®Google Scholar
• Evans W, Osoba D, Feld R, et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small cell lung cancer. J Clin Oncol 1985; 3: 36–71
   Google Scholar
• Kessinger A, Foley J F, Lemon M H. Can maximum benefit be achieved with lower dosages and less toxicity in the chemo-therapeutic management of small cell lung cancer?. Proc Am Soc Clin One 1983; 2: 186
   Google Scholar
• Einhorn L, Bond W H, Hornback W, et al. Long term results in combined modality treatment of small cell lung cancer. Sem Oncol 1978; 5: 309–313
   PubMed Web of Science ®Google Scholar
• Livingston R B, Greenstreet R L. Reinduction prolongs survival in complete responders (CR) with small cell lung cancer. Proc Am Soc Clin Oncol 1982; 1: 151
   Google Scholar
• Abeloff M D, Ettinger D S, Order S E, et al. Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat Rep 1981; 65: 639–646
   PubMedGoogle Scholar
• Smith I., Sappino A, Bondy P, et al. Long-term survival five years or more after combination chemotherapy and radiotherapy for small cell lung carcinoma. Eur J Cancer Clin Oncol 1981; 11: 1249–1253
   Google Scholar
• Souhami R, Harper P, Ling D, et al. Higher dose cyclophosphamide with autologous marrow transplantation on initial treatment of small cell carcinoma of the bronchus. Cancer Chemother Pharm 1982; 8: 31–34
   PubMed Web of Science ®Google Scholar
• Feld R, Evans W K, DeBoer G, et al. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 1984; 2: 294–304
   PubMed Web of Science ®Google Scholar
• Vogl S E, Mehta C. High-dose cyclophosphamide in the induction chemotherapy of small cell lung cancer-minor improvements in the rate of remission and in survival. III World Conf Lung Cancer, Japan, 1982; 168, Abstracts
   Google Scholar
• Hande K, Oldham R, Fer M, et al. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 1982; 73: 413–419
   PubMed Web of Science ®Google Scholar
• Johnson D H, Wolff S N, Porter L L, et al. Combination high-dose (HD) VP-16–213 (E) cyclophosphamide (C) chemotherapy (CT) without bone marrow transplantation (BMT) for extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1984; 3: 215
   Google Scholar
• Brower M, Ihde D C, Johnston-Early A. Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy. Am J Med 1983; 75: 993–1000
   PubMed Web of Science ®Google Scholar
• Thomas E D, Buckner C D, Clift R, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–599
   PubMed Web of Science ®Google Scholar
• Ihde D C, Lichter A S, Deisseroth A B, et al. Late intensive combined modality therapy with autologous bone marrow infusion in extensive stage small cell lung cancer. Proc. 13th International Congress of Chemotherapy, Egermann, Vienna, 1983; 281/5–281/8
   Google Scholar
• Klastersky J, Nicaise C, Longeval E, et al. Cisplatin, adriamycin and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone-marrow rescue. Cancer 1982; 50: 652–658
   PubMed Web of Science ®Google Scholar
• Stewart P, Buckner C D, Thomas E D., et al. Intensive chemo-radiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 1983; 67: 1055–1059
   PubMedGoogle Scholar
• Combleet M, Gregor A, Allan S, et al. High dose melphalan as consolidation therapy for good prognosis patients with small cell carcinoma of bronchus (SCCB). Proc Am Soc Clin Oncol 1984; 3: 210
   Google Scholar
• Rosen S, Mulshine J, Cuttitta F, et al. Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res 1984; 44: 2052–2061
   PubMed Web of Science ®Google Scholar
• Spitzer G, Farha P, Dicke K, et al. High dose intensification with autologous bone marrow transplantation (ABMT) in limited small cell bronchogenic carcinoma (SCBC). Proc Am Soc Clin Oncol 1984; 3: 221
   Google Scholar
• Perez C A, Einhorn L., Oldham R K, et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: A preliminary report. J Clin Oncol 1984; 2: 1200–1208
   PubMed Web of Science ®Google Scholar
• Shank B, Natale R B, Hilaris B S, et al. Treatment of small cell carcinoma of lung with combined high dose mediastinal irradiation, whole brain prophylaxis and chemotherapy. Int J Rad Oncol Biol Phys 1981; 7: 469–475
   PubMed Web of Science ®Google Scholar
• Scher H, Chapman R, Shank B, et al. Combination chemotherapy (CT) and radiotherapy (RT) with and without thymosin (T) in small cell lung cancer (SCLC). III World Conf Lung Cancer, Japan, 1982; 155, Abstracts
   Google Scholar
• Goodman G E, Miller T P, Manning M M, et al. Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin). cyclophosphamide (EVAC), and high-dose chest radiotherapy. J Clin Oncol 1983; 1: 483–488
   PubMed Web of Science ®Google Scholar
• Feld R. Complications in the treatment of small cell carcinoma of the lung. Cancer Treat Rep 1981; 8: 5–25
   Google Scholar
• Markman M, Pavy M, Abeloff M. Acute leukemia following intensive therapy for small-cell carcinoma of the lung. Cancer 1982; 50: 672–675
   PubMed Web of Science ®Google Scholar
• Johnson B E, Ihde D C, Lichter A S, et al. Five to 10 year follow-up of small cell lung cancer (SCLC) patients disease free at 30 months: Chronic toxicities and late relapses. Proc Am Soc Clin One 1984; 3: 218
   Google Scholar
• Byhardt R W, Cox J D, Holoye P Y, et al. The role of consolidation irradiation in combined modality therapy of small cell carcinoma of the lung. lnt J Rad Oncol Biol Phys 1982; 8: 1271–1276
   PubMed Web of Science ®Google Scholar
• Thatcher N, Hunter R, Jegarajah S, et al. Eleven-week course of sequential methotrexate, thoracic irradiation and moderate-dose cyclophosphamide for “limited” stage small cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. Lancet 1982; 1: 1040–1042
   PubMed Web of Science ®Google Scholar
• Johnson R, Brereton H, Kent C. Total therapy for small cell carcinoma of the lung. Ann Thor Surg 1978; 25: 510–515
   PubMed Web of Science ®Google Scholar
• Woods R L, Levi J A. Chemotherapy for small ceil lung cancer (SCLC): a randomized study of maintenance therapy with cyclophosphamide, adriamycin and vincristine (CAV) after remission induction with cis-platinum (cis-DDP), VP-16–213 and radiotherapy. Proc Am Soc Clin Oncol 1984; 3: 214
   Google Scholar
• Lenhard R, Woo K, Abeloff M. Predictive value of regression rates following chemotherapy of small cell carcinoma of the lung. Cancer Res 1983; 43: 3013–3017
   PubMed Web of Science ®Google Scholar
• Carney D N, Broder L, Edelstein M, et al. Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep 1983; 67: 27–36
   PubMedGoogle Scholar
• Carney D N, Mitchell J B, Kinsella T J. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 1983; 43: 2806–2811
   PubMed Web of Science ®Google Scholar
• Whang-Peng J, Kao-Shan C, Lee E, et al. Specific chromosome defect associated with human small cell lung cancer: Deletion 3p (14–23). Science 1982; 215: 191–192
   Google Scholar
• Eagen R T, Carr D T, Frytak S, et al. VP-16–213 versus poly-chemotherapy in patients with advanced small cell lung cancer. Cancer Treat Rep 1976; 60: 949–951
   PubMedGoogle Scholar
• Harper P C, Dally M B, Geddes D M, et al. Epipodophyllotoxin (VP16–213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy. Cancer Chemother Pharmacol 1982; 7: 179–180
   PubMed Web of Science ®Google Scholar
• Antman K, Pomfret E, Karp G, et al. Phase II trial of etoposide in previously treated patients with small cell carcinoma of the lung. Cancer Treat Rep 1984; 68: 1413–1414
   PubMedGoogle Scholar
• Issell B F, Einhorn L H, Comis R L, et al. Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treat Rep 1985; 69: 127–128
   PubMedGoogle Scholar
• Natale R, Gralla R, Wittes R. Phase II trial of vindesine in patients with small cell lung carcinoma. Cancer Treat Rep 1981; 65: 129–131
   PubMedGoogle Scholar
• Chang A Y, Witte R S, Tormey D C, et al. Evaluation of vindesine in patients with refractory small cell lung cancer. Cancer Treat Rep 1984; 68: 1407–1408
   PubMedGoogle Scholar
• Osterlind K, Dombernowsky P, Sorenson P, et al. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 1981; 65: 145–148
   Google Scholar
• Smith I E, Harland S J, Robinson B A, et al. Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985; 69: 43–46
   PubMedGoogle Scholar
• Madajewicz S, Takita H, Creaven P, et al. Phase II study of iproplatin (IPP) in small cell carcinoma of the lung (SCCL). Proc Am Soc Clin One 1984; 3: 225
   Google Scholar
• Cohen E, Gralla R, Kris M, et al. Phase II studies in small cell lung cancer (SCLC); an analysis of 97 trials. Proc Am Soc Clin Oncol 1985; 4: 190
   Google Scholar
• Jackson D V, ZeKan P J, Caldwell R D, et al. VP-16–213 in combination chemotherapy with chest irradiation for small-cell-lung cancer: A randomized trial of the Piedmont Oncology Association. J Clin Oncol 1984; 2: 1343–1351
   PubMed Web of Science ®Google Scholar
• Nugent J L, Bunn P A, Matthews M J, et al. CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival. Cancer 1979; 44: 1885–1893
   PubMed Web of Science ®Google Scholar
• Doyle T J. Brain metastasis in the natural history of small-cell lung cancer 1972–1979. Cancer 1982; 50: 752–754
   PubMed Web of Science ®Google Scholar
• Ihde D C, Makuch R W, Carney D N, et al. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Resp Dis 1981; 123: 500–507
   PubMed Web of Science ®Google Scholar
• Bunn P A, Nugent J L, Matthews M J. Central nervous system metastases in small cell bronchogenic carcinoma. Sem Oncol 1978; 5: 314–322
   PubMed Web of Science ®Google Scholar
• Komaki R, Cox J D, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep 1981; 65: 811–814
   PubMedGoogle Scholar
• Jackson D V, Richards F, Cooper R, et al. Prophylactic cranial irradiation in small cell carcinoma of the lung. JAMA 1977; 237: 2730–2733
   PubMed Web of Science ®Google Scholar
• Seydel H G, Crrech R, Pagano M, et al. Combined modality treatment of regional small cell undifferentiated carcinoma of the lung: A cooperative study of the RTOG and ECOG. Int J Rad Oncol Biol Phys 1983; 9: 1135–1141
   PubMed Web of Science ®Google Scholar
• Beiler D D, Kane R C, Bernath A M, et al. Low dose elective brain irradiation in small cell carcinoma of the lung. Int J Rad Oncol Biol Phys 1979; 5: 941–945
   PubMed Web of Science ®Google Scholar
• Maurer L H, Tulloh M, Weiss R B, et al. A randomized combined modality trial in small cell carcinoma of the lung: Comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 1980; 45: 30–39
   PubMed Web of Science ®Google Scholar
• Cox J D, Petrovich Z, Paig C, et al. Prophylactic cranial irradiation with inoperable carcinoma of the lung: Preliminary report of a cooperative trial. Cancer 1978; 42: 1135–1140
   PubMed Web of Science ®Google Scholar
• Hirsch F R, Hansen H H, Paulson O B, . Development of brain metastases in small-cell anaplastic carcinoma of the lung. CNS Complications of Malignant Disease, J MA White-House, H EM Kay, et al. Macmillan, New York 1979; 175–184
   Google Scholar
• Rosen S T, Makuch R W, Lichter A S, et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer: Potential benefit restricted to patients with complete response. Am J Med 1983; 74: 615–624
   PubMed Web of Science ®Google Scholar
• Aroney R S, Aisner J, Wesley M N, et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 1983; 67: 675–682
   PubMedGoogle Scholar
• Ellison N, Bernath A, Kane R, et al. Disturbing problems of success: Clinical status of long-term survivors of small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1982; 1: 149
   Google Scholar
• Walker R, Lazar R M, Gralla R, et al. Neuropsychological abnormalities in long term survivors of small cell lung cancer receiving prophylactic cranial irradiation. Am Soc Clin One 1985, Submitted to
   Google Scholar
• Licciardello J, Bromer R, Karp D, et al. Delayed neurotoxicity (DN) after prophylactic cranial irradiation (PCXRT) or mediastinal irradiation with chemotherapy for patients with small cell lung cancer. Proc Am Soc Clin One 1983; 2: 189
   Google Scholar
• Scher H, Hilaris B, Wittes R. Long term follow-up of combined modality therapy in small cell carcinoma (SCLC) of the lung. Proc Am Soc Clin One 1983; 2: 199
   Google Scholar
• Livingston R B, Stephens R L, Bonnet J D, et al. Long-term survival and toxicity in small cell lung cancer: A Southwest Oncology Group study. Am J Med 1984; 77: 415–417
   PubMed Web of Science ®Google Scholar
• Looper J D, Einhorn L H, Garcia S A, et al. Severe neurologic problems following successful therapy for small cell lung cancer (SCLC). Proc Am Soc Clin One 1984; 3: 231
   Google Scholar
• Lee J S, Lee Y Y, Umsawasdi T, et al. Neurotoxicity (NT) in long-term survivors (LTS) of small cell lung cancer (SCLC). Proc Am Soc Clin One 1984; 3: 220
   Google Scholar
• Mira J G, Chen T, Livingston R B. Evaluation of prophylactic brain irradiation (PB1) vs. therapeutic irradiation (TBI) in disseminated small cell lung carcinoma (SCLC): A Southwest Oncology Group (SWOG) study. Int J Rad Oncol Biol Phys 1983; 9: 122
   Google Scholar
• Catane R, Schwade J G, Yarr I, et al. Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. Int J Rad Oncol Biol Phys 1981; 7: 105–109
   PubMed Web of Science ®Google Scholar
• Rosenman J, Choi N C. Improved quality of life of patients with small-cell carcinoma of the lung elective irradiation of the brain. Int J Rad Oncol Biol Phys 1981; 8: 1041–1043
   Web of Science ®Google Scholar
• Crane J, Nelson M, Ihde D, et al. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. J Clin Oncol 1984; 2: 1017–1024
   PubMed Web of Science ®Google Scholar
• Byhardt R W, Cox J D. Is chest radiotherapy necessary in any or all patients with small cell carcinoma of the lung? Yes. Cancer Treat Rep 1983; 67: 209–215
   PubMedGoogle Scholar
• Ochs J J, Tester W J, Cohen M H, et al. “Salvage” radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 1983; 67: 1123–1126
   PubMedGoogle Scholar
• Looper J D, Hornback N B. The role of chest irradiation in limited small cell carcinoma of the lung treated with combination chemotherapy. Int J Rad Oncol Biol Phys 1984; 10: 1855–1860
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Hansen H H, Hansen M, et al. Treatment of small cell anaplastic bronchogenic carcinoma. Results from 2 randomized trials. II World Conf Lung Cancer. Copenhagen. Excerpta Medica, Amsterdam 1980; 149, Abstracts
   Google Scholar
• Hansen H H, Dombernowsky P, Hansen H S, et al. Chemotherapy versus chemotherapy plus radiotherapy in regional small-cell carcinoma of the lung-a randomized trial. Proc Am Assoc Cancer Res 1979; 20: 277
   Web of Science ®Google Scholar
• Souhami R L, Geddes D M, Spiro S G, et al. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: A controlled trial. Br Med J 1984; 288: 1643–1646
   PubMed Web of Science ®Google Scholar
• Fox R M, Woods R L, Brodie G N, et al. A randomized study: Small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int J Rad Oncol Biol Phys 1980; 6: 1083–1085
   PubMed Web of Science ®Google Scholar
• Fox R M, Tattersall M HN, Woods R L. Radiation therapy as an adjuvant in small cell lung cancer treated by combination chemotherapy: A randomized study. Proc Am Soc Clin One 1981; 22: 502
   Google Scholar
• Ihde D C, et al. Fourth Int Conf Adjuvant Ther Cancer. Reported in Clin Cancer Letter 1984; 7: 3
   Google Scholar
• Lichter A S, Bunn P A, Ihde D C, et al. The role of radiation therapy in the treatment of small cell lung cancer. Nat Conf Rad Oncol, Am Cancer Soc, San Francisco, CA, 1984, Abstract
   Google Scholar
• Bunn P., Cohen M, Lichter A, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy in limited stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1983; 2: 200
   Google Scholar
• Perez C, Einhorn L, Oldham R K, et al. Value of radiation therapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation. J Clin Oncol 1984; 2: 1200–1208
   PubMed Web of Science ®Google Scholar
• Perry M C, Eaton W L, Ware J, et al. Chemotherapy (CT) with or without radiation therapy (RT) in limited small cell cancer of the lung (SCCL). Proc Am Soc Clin Oncol 1984; 3: 230
   Google Scholar
• Morgan D AL. Radiotherapy in small cell cancer of the lung. Letter, Br Med J 1984; 289: 189–190
   Web of Science ®Google Scholar
• Choi C H, Carey R W. Small cell anaplastic carcinoma of the lung: Reappraisal of current management. Cancer 1976; 37: 2651–2657
   PubMed Web of Science ®Google Scholar
• Cox J D, Byhardt R W, Wilson J F, et al. Dose-time relationships and the local control of small cell carcinoma of the lung. Radiology 1978; 128: 205–207
   PubMed Web of Science ®Google Scholar
• Eaton W L, Maurer H, Glicksman A, et al. The relationship of infield recurrences to prescribed tumor dose in small cell carcinoma of the lung. Int J Rad Oncol Biol Phys 1981; 7: 1223
   Web of Science ®Google Scholar
• Bleehen N M, Bunn P A, Cox J D, et al. Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep 1983; 67: 11–19
   PubMedGoogle Scholar
• Goodman G E, Manning M R, Ketchel S, . Improved survival in small cell lung cancer treated with combination (EVAC) and high dose adjuvant radiotherapy (XRT). Adjuvant Therapy of Cancer III, S Salmon, S Jones, et al. Grune and Stratton, New York 1981
   Google Scholar
• Shank B, Scher H, Hilaris B, et al. Increased survival with high dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of lung. Int J Rad Oncol Biol Phys 1983; 9: 122–123
   Google Scholar
• Martini N. Surgery. Commentary-treatment of small cell undifferentiated carcinoma of the lung: Update of recent results, R B Weiss, J D Minna, E Glatstein, et al, 1980; 64: 539–548, Cancer Treat Rep
   Google Scholar
• Foster J M, Prager R L, Hainsworth J D, et al. Limited-stage small-cell carcinoma (SCC): Prospective evaluation regarding the feasibility of adjuvant surgery. Proc Am Soc Clin One 1983; 2: 196
   Google Scholar
• Hande K R, DesPrez R M. Current perspectives in small cell lung cancer. Chest 1984; 85: 669–677
   PubMed Web of Science ®Google Scholar
• Higgins G A, Shields T W, Keehn R J. The solitary pulmonary nodule: ten-year followup of Veterans Administration-Armed Forces cooperative study. Arch Surg 1975; 110: 570–575
   PubMed Web of Science ®Google Scholar
• Shields T W, Higgins G A, Matthews M J, et al. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982; 84: 481–488
   PubMed Web of Science ®Google Scholar
• Shore D F, Paneth M. Survival after resection of small cell carcinoma of the bronchus. Thorax 1980; 35: 819–822
   PubMed Web of Science ®Google Scholar
• Meyer J A, Comis R L, Ginsberg S J, et al. Phase II trial of extended indications for resection in small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982; 83: 12–19
   PubMed Web of Science ®Google Scholar
• Comis R, Meyer J, Ginsberg S, et al. The impact of TNM stage on results with chemotherapy (CT) and adjuvant surgery (AS) in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1984; 3: 226
   Google Scholar
• Valdivieso M, McMurtrey M J, Farha P, et al. Prospective evaluation of adjuvant surgical resection (ASR) in small cell lung cancer (SCLC). Proc Am Soc Clin One 1984; 3: 220
   Google Scholar
• Shepherd F A, Ginsberg R, Evans W K, et al. “Very limited” small cell lung cancer (SCLC) results of non-surgical treatment. Proc Am Soc Clin One 1984; 3: 223
   Google Scholar
• Karrer K, Pridun N, Denck H. Small cell bronchial carcinoma radically operated adjuvant for polychemotherapy. II World Conf Lung Cancer. Abstracts. Copenhagen. Excerpta Medica, Amsterdam 1980; 155
   Google Scholar
• Friess G, McCracken J, Clark G, et al. Improved long term survival associated with surgery in limited small cell cancer of the lung (SCCL). A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin One 1984; 3: 219
   Google Scholar
• Brambilla C, Grance C, Carpentier F, et al. Immunologic monitoring of patients with small cell anaplastic carcinoma who are treated with chemotherapy and radiotherapy. Int J Rad Oncol Biol Phys 1980; 6: 1057–1060
   PubMed Web of Science ®Google Scholar
• McCracken J D, Heilbrun L, White J, et al. Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung. Cancer 1980; 46: 2335–2340
   PubMed Web of Science ®Google Scholar
• McCracken J D, Chen T, White J, et al. Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung. Cancer 1982; 49: 2252–2258
   PubMed Web of Science ®Google Scholar
• Cohen M H, Chretien P B, Ihde D C, et al. Thymosin fraction V and intensive combination chemotherapy: Prolonging the survival of patients with small-cell lung cancer. JAMA 1979; 241: 1813–1815
   PubMed Web of Science ®Google Scholar
• Minna J. Recent advances of potential clinical importance in the biology of lung cancer. The Richard and Hinda Rosenthal Foundation Lecture. Proc Am Assoc Can Res 1984; 25: 393–394
   Google Scholar